MicroRNA: Trends in Clinical Trials of Cancer Diagnosis and Therapy Strategies

Overview

Journal Exp Mol Med

Specialties Biochemistry
Molecular Biology

Date 2023 Jul 10

PMID 37430087

Authors

Taewan Kim

Carlo M Croce

Affiliations

Soon will be listed here.

Abstract

As a type of short noncoding RNAs, microRNA (miRNA) undoubtedly plays a crucial role in cancer development. Since the discovery of the identity and clinical functions of miRNAs, over the past few decades, the roles of miRNAs in cancer have been actively investigated. Numerous pieces of evidence indicate that miRNAs are pivotal factors in most types of cancer. Recent cancer research focused on miRNAs has identified and characterized a large cohort of miRNAs commonly dysregulated in cancer or exclusively dysregulated in specific types of cancer. These studies have suggested the potential of miRNAs as biomarkers in the diagnosis and prognostication of cancer. Moreover, many of these miRNAs have oncogenic or tumor-suppressive functions. MiRNAs have been the focus of research given their potential clinical applications as therapeutic targets. Currently, various oncology clinical trials using miRNAs in screening, diagnosis, and drug testing are underway. Although clinical trials studying miRNAs in various diseases have been reviewed before, there have been fewer clinical trials related to miRNAs in cancer. Furthermore, updated results of recent preclinical studies and clinical trials of miRNA biomarkers and drugs in cancer are needed. Therefore, this review aims to provide up-to-date information on miRNAs as biomarkers and cancer drugs in clinical trials.

Citing Articles

Profiling of miRNAs Contained in Circulating Extracellular Vesicles and Associated with Sepsis Development in Burn Patients: A Proof-of-Concept Study.

Schiavello M, Bosco O, Vizio B, Sciarrillo A, Pensa A, Pivetta E Int J Mol Sci. 2025; 26(5).

PMID: 40076471 PMC: 11899136. DOI: 10.3390/ijms26051844.

MicroRNA 320a-3p up-regulation reduces PD-L1 expression in gastric cancer cells: an experimental and bioinformatic study.

Asghariazar V, Makaremi S, Amani N, Zare E, Kadkhodayi M, Eterafi M Sci Rep. 2025; 15(1):8239.

PMID: 40065071 PMC: 11894147. DOI: 10.1038/s41598-025-92537-0.

Exploring precision treatments in immune-mediated inflammatory diseases: Harnessing the infinite potential of nucleic acid delivery.

Xu L, Shao Z, Fang X, Xin Z, Zhao S, Zhang H Exploration (Beijing). 2025; 5(1):20230165.

PMID: 40040830 PMC: 11875455. DOI: 10.1002/EXP.20230165.

Exosome-based miRNA delivery: Transforming cancer treatment with mesenchymal stem cells.

Balaraman A, Babu M, Afzal M, Sanghvi G, M M R, Gupta S Regen Ther. 2025; 28:558-572.

PMID: 40034540 PMC: 11872554. DOI: 10.1016/j.reth.2025.01.019.

Identification of novel diagnostic and prognostic microRNAs in sarcoma on TCGA dataset: bioinformatics and machine learning approach.

Rahmati R, Zarimeidani F, Ahmadi F, Yousefi-Koma H, Mohammadnia A, Hajimoradi M Sci Rep. 2025; 15(1):7521.

PMID: 40032929 PMC: 11876432. DOI: 10.1038/s41598-025-91007-x.

References

Ambros V . The functions of animal microRNAs. Nature. 2004; 431(7006):350-5. DOI: 10.1038/nature02871. View

Wightman B, Ha I, Ruvkun G . Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell. 1993; 75(5):855-62. DOI: 10.1016/0092-8674(93)90530-4. View

Lee R, Feinbaum R, Ambros V . The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75(5):843-54. DOI: 10.1016/0092-8674(93)90529-y. View

Kim T, Croce C . MicroRNA and ER stress in cancer. Semin Cancer Biol. 2021; 75:3-14. DOI: 10.1016/j.semcancer.2020.12.025. View

Jame-Chenarboo F, Ng H, Macdonald D, Mahal L . High-Throughput Analysis Reveals miRNA Upregulating α-2,6-Sialic Acid through Direct miRNA-mRNA Interactions. ACS Cent Sci. 2022; 8(11):1527-1536. PMC: 9686205. DOI: 10.1021/acscentsci.2c00748. View

Laitinen P, Vaananen M, Kolari I, Makinen P, Kaikkonen M, Weinberg M . Nuclear microRNA-466c regulates Vegfa expression in response to hypoxia. PLoS One. 2022; 17(3):e0265948. PMC: 8975276. DOI: 10.1371/journal.pone.0265948. View

Calin G, Dumitru C, Shimizu M, Bichi R, Zupo S, Noch E . Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002; 99(24):15524-9. PMC: 137750. DOI: 10.1073/pnas.242606799. View

He L, He X, Lim L, de Stanchina E, Xuan Z, Liang Y . A microRNA component of the p53 tumour suppressor network. Nature. 2007; 447(7148):1130-4. PMC: 4590999. DOI: 10.1038/nature05939. View

Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N . Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell. 2007; 26(5):731-43. DOI: 10.1016/j.molcel.2007.05.017. View

10.

Kim T, Veronese A, Pichiorri F, Lee T, Jeon Y, Volinia S . p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med. 2011; 208(5):875-83. PMC: 3092351. DOI: 10.1084/jem.20110235. View

11.

ODonnell K, Wentzel E, Zeller K, Dang C, Mendell J . c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005; 435(7043):839-43. DOI: 10.1038/nature03677. View

12.

Calin G, Croce C . MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6(11):857-66. DOI: 10.1038/nrc1997. View

13.

Chakraborty C, Sharma A, Sharma G, Lee S . Therapeutic advances of miRNAs: A preclinical and clinical update. J Adv Res. 2020; 28:127-138. PMC: 7753224. DOI: 10.1016/j.jare.2020.08.012. View

14.

Doebele C, Bonauer A, Fischer A, Scholz A, Reiss Y, Urbich C . Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Blood. 2010; 115(23):4944-50. DOI: 10.1182/blood-2010-01-264812. View

15.

Abplanalp W, Fischer A, John D, Zeiher A, Gosgnach W, Darville H . Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study. Nucleic Acid Ther. 2020; 30(6):335-345. DOI: 10.1089/nat.2020.0871. View

16.

Lee T, Matta B, King B, Hodges M, Tillmann H, Patel K . MicroRNA-122 associates with serum apolipoprotein B but not liver fibrosis markers in CHC genotype 1 infection. J Med Virol. 2015; 87(10):1722-6. DOI: 10.1002/jmv.24230. View

17.

Patel V, Williams D, Hajarnis S, Hunter R, Pontoglio M, Somlo S . miR-17~92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease. Proc Natl Acad Sci U S A. 2013; 110(26):10765-70. PMC: 3696812. DOI: 10.1073/pnas.1301693110. View

18.

Lee E, Valencia T, Allerson C, Schairer A, Flaten A, Yheskel M . Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease. Nat Commun. 2019; 10(1):4148. PMC: 6742637. DOI: 10.1038/s41467-019-11918-y. View

19.

Bais T, Gansevoort R, Meijer E . Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease. Drugs. 2022; 82(10):1095-1115. PMC: 9329410. DOI: 10.1007/s40265-022-01745-9. View

20.

Hanna J, Hossain G, Kocerha J . The Potential for microRNA Therapeutics and Clinical Research. Front Genet. 2019; 10:478. PMC: 6532434. DOI: 10.3389/fgene.2019.00478. View